
Inozyme Pharma Investor Relations Material
Latest events

Study Update
Inozyme Pharma

Q1 2025
13 May, 2025

Q4 2024
10 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Inozyme Pharma Inc
Access all reports
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases that affect the vasculature, soft tissue, and skeleton. The company's research is centered on disorders related to the PPi-Adenosine Axis, a pathway crucial for mineralization and vascular health. Disruptions in this pathway can lead to severe conditions such as ENPP1 and ABCC6 deficiencies, which Inozyme targets with its lead product candidate, INZ-701. This enzyme replacement therapy is designed to address pathologic mineralization and intimal proliferation, aiming to reduce the morbidity and mortality associated with these conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
INZY
Country
🇺🇸 United States